Source: Advanced Proteome Therapeutics Corp.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Advanced Proteome Therapeutics Corporation’s (APC) U.S. subsidiary has been issued a patent
  • The patent covers highly site-selective antibody conjugate compositions produced with APTI’s two-step conjugation technology
  • APTI is continuing to pursue expanded claims and additional patents
  • Advanced Proteome Therapeutics has invented proprietary protein conjugation technology enabling the development of superior antibody-drug conjugates
  • Advanced Proteome Therapeutics Corp. (APC) is up 15.79 per cent on the day, trading at C$0.22 per share at 2:15 pm ET

Advanced Proteome Therapeutics Corporation’s (APC) U.S. subsidiary has been issued a patent from the United States Patent and Trademark Office.

Advanced Proteome Therapeutics Inc. (APTI) was issued U.S. Patent No. 11,400,165 titled ‘Composition and method for modifying polypeptides’. The patent covers highly site-selective antibody conjugate compositions produced with APTI’s two-step conjugation technology.

The patent term, including patent term adjustment, is expected to extend into November 2039. This is the first patent issued under US patent application 16/180,960.

APTI is continuing to pursue expanded claims and additional patents within the initial application in order to create additional layers of intellectual property protection.

Dr. Benjamin Krantz, President and CEO of APTI commented on the news.

“The issuance of this patent is a critical milestone for APTI. The patent provides market exclusivity to highly site-selective ADC compositions that are created with our two-step antibody conjugation approach. This protection greatly enhances our ability to monetize our invention and increases our attractiveness to potential collaborators. This is another step forward in our 2022 plan and I look forward to other successes in the near future.”

Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., has invented proprietary protein conjugation technology enabling the development of superior antibody-drug conjugates. The company believes that the technology will enable the development of safer and more potent antibody-drug conjugate therapeutics and is pursuing licensing and partnership opportunities to advance development.

Advanced Proteome Therapeutics Corp. (APC) is up 15.79 per cent on the day, trading at C$0.22 per share at 2:15 pm ET.


More From The Market Herald

" MCI Onehealth (TSX:DRDR) and Euclid Telehealth work to improve patient vision

MCI Onehealth (DRDR) and Euclid Telehealth are collaborating to increase access to care that can potentially prevent vision loss among Ontario patients.

" Spectral Medical (TSX:EDT) reports Q2 2022 results

Spectral Medical (EDT) released its financial results for the second quarter ended June 30, 2022.

" Hemostemix (TSXV:HEM) closes second tranche of non-brokered private placement

Hemostemix (HEM) has closed the second tranche of a non-brokered private placement of units for gross proceeds of $1,364,710.10.

" Nova Leap Health (TSXV:NLH) posts 2nd highest Q2 results in its history

Nova Leap Health (NLH) released its financial results for the quarter ended June 30, 2022.